CombiMatrix Molecular Diagnostics this week launched its ProScan test for prostate cancer.
Â
The array comparative genomic hybridization-based ProScan test comprises probes for specific genomic loci of which copy number gains and losses have been shown to correlate with risk of recurrence and metastasis in patients post-prostatectomy, CMDX said.
Â
The additional probes are an enhancement of the CMDX solid tumor array platform design which enables whole-genome tumor profiling, or genomic grading, while also providing information about the copy-number status of specific disease-associated loci, the firm said.
Â
ProScan is available through CMDX’s CLIA-compliant lab in Irvine, Calif.